CSPC Innovation Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
CSPC Innovation Pharmaceutical Co., Ltd. carries a market capitalization of 47.98B, placing it among publicly traded companies globally. Its enterprise value stands at 71.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 47.98B |
| Enterprise Value | 71.73B |
Share Statistics
CSPC Innovation Pharmaceutical Co., Ltd. currently has 1.40B shares outstanding.
| Shares Outstanding | 1.40B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CSPC Innovation Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 173.72. The price-to-sales ratio is 35.18, and the price-to-book ratio stands at 26.92.
| PE Ratio | 173.72 |
| PS Ratio | 35.18 |
| PB Ratio | 26.92 |
| P/TBV Ratio | 17.79 |
| P/FCF Ratio | 187.87 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 34.85 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 179.90 |
Financial Position
CSPC Innovation Pharmaceutical Co., Ltd. maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.01, indicating conservative leverage, while an interest coverage ratio of -41.89 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.65 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | -41.89 |
Financial Efficiency
| Return on Equity (ROE) | -3.12 |
| Return on Assets (ROA) | -1.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.41 |
Taxes
| Income Tax | 74.44M |
| Effective Tax Rate | N/A |
Stock Price Statistics
CSPC Innovation Pharmaceutical Co., Ltd.'s stock has declined approximately -33.33333% over the past 52 weeks. The 50-day moving average sits at 28.27, while the 200-day moving average is 33.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.33333% |
| 50-Day Moving Average | 28.27 |
| 200-Day Moving Average | 33.65 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CSPC Innovation Pharmaceutical Co., Ltd. generated 2.06B in revenue and converted that into -86.05M in net income, yielding earnings per share of -0.37. EBITDA reached -473.75M, while operating income came in at -473.75M.
| Revenue | 2.06B |
| Gross Profit | 806.24M |
| Operating Income | -473.75M |
| Pretax Income | -443.97M |
| Net Income | -86.05M |
| EBITDA | -473.75M |
| EBIT | -473.75M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
CSPC Innovation Pharmaceutical Co., Ltd. holds 1.28B in cash and equivalents against 601,180.65 in total debt, resulting in a net debt position of -815.53M. Total book value stands at 2.69B, with working capital of 1.13B providing operational flexibility.
| Cash & Cash Equivalents | 1.28B |
| Total Debt | 601,180.65 |
| Net Debt | -815.53M |
| Equity (Book Value) | 2.69B |
| Book Value Per Share | 1.92 |
| Working Capital | 1.13B |
Cash Flow
After subtracting -385.50M in capital expenditures, free cash flow totaled -385.50M - equivalent to -0.28 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -385.50M |
| Free Cash Flow | -385.50M |
| FCF Per Share | -0.28 |
Margins
CSPC Innovation Pharmaceutical Co., Ltd. operates with a gross margin of 39.17, reflecting its pricing power and cost economics. The operating margin of -23.02 and net profit margin of -4.18 provide insight into operational efficiency.
| Gross Margin | 39.17 |
| Operating Margin | -23.02 |
| Pretax Margin | -21.57 |
| Profit Margin | -4.18 |
| EBITDA Margin | -23.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.66 |
| FCF Yield | 0.53 |
Stock Splits
CSPC Innovation Pharmaceutical Co., Ltd.'s most recent stock split took place on April 25, 2024 with a 5:6 split ratio.
| Last Split Date | 4/25/2024 |
| Split Ratio | 5:6 |
Scores
CSPC Innovation Pharmaceutical Co., Ltd. posts an Altman Z-Score of 23.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 23.81 |